Originally published by our sister publication Gastroenterology & Endoscopy News
The FDA approved the first oral suspension of budesonide (Eohilia, Takeda) for patients with eosinophilic esophagitis who are 11 years of age and older.
The new oral formulation of budesonide will be available in 2-mg/10-mL single-dose stick packs by the end of February, according to Takeda.
The approval follows positive results from two 12-week, multicenter, double-blind, randomized controlled trials (Study 1,